Loading
Amrubicin / Topotecan / Ifinatamab deruxtecan · Phase 3 Trial
ClinicalTrials.gov · August 5, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 registry entry for an ongoing randomized trial comparing ifinatamab deruxtecan to physician's choice of chemotherapy in relapsed small cell lung cancer, with overall survival as the primary endpoint over approximately 3.7 years. No efficacy or safety results are reported in this registry record; the trial remains in recruitment phase.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Small Cell Lung Cancer; age from 18 Years. Intervention: Ifinatamab deruxtecan (I-DXd). Compared with: Treatment of Physician's Choice (TPC) — Active Comparator. n = 540. 229 sites across 23 countries.
This is a Phase 3 registry entry for an ongoing randomized trial comparing ifinatamab deruxtecan to physician's choice of chemotherapy in relapsed small cell lung cancer, with overall survival as the primary endpoint over approximately 3.7 years. No efficacy or safety results are reported in this registry record; the trial remains in recruitment phase.
No efficacy, safety, or outcome data are reported in this registry record; trial is actively recruiting
Once results are available, this trial will provide evidence on whether ifinatamab deruxtecan improves overall survival compared to standard chemotherapy options in the relapsed SCLC setting. Clinicians should await completion and publication of outcome data before drawing clinical conclusions.
Phase 3 randomized trial of ifinatamab deruxtecan versus physician's choice in relapsed SCLC; registry record with no results posted, so efficacy and safety remain unreported.
As stated by the source record.
Quoted from the source exactly as published.
Once results are available, this trial will provide evidence on whether ifinatamab deruxtecan improves overall survival compared to standard chemotherapy options in the relapsed SCLC setting. Clinicians should await completion and publication of outcome data before drawing clinical conclusions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06203210). This is a study registration, not published results. Lead sponsor: Daiichi Sankyo. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 540 participants (ESTIMATED). Conditions: Small Cell Lung Cancer. Interventions: DRUG: Ifinatamab deruxtecan; DRUG: Topotecan; DRUG: Amrubicin; DRUG: Lurbinectedin. Primary outcome measures: Overall Survival (OS) , From the date of randomization to the date of death due to any cause, up to approximately 3.7 years. Brief summary: This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.